On August 7, 2026, OnKure Therapeutics repriced approximately 1.7 million underwater stock options held by employees and consultants to a new exercise price of $4.14 per share, matching the closing stock price on that date. The repricing applied to options granted prior to January 1, 2025, with original exercise prices between $13.99 and $24.59. Named executive officers Nicholas Saccomano, Samuel Agresta, and Jason Leverone received repriced options covering 863,121 shares combined. Retention requirements mandate continued service for 18 months for senior management or one year for other employees; failure to meet these terms triggers a premium exercise price equal to the original strike. This action aims to retain talent without incurring additional dilution from new grants or cash compensation costs. OnKure Therapeutics operates in the biotechnology industry, focusing on developing novel therapies.

OnKure Therapeutics reported financial results for the quarter ended June 30, 2026. The company held $176.4 million in cash and equivalents, providing a runway into 2029. Research and development expenses were $12.6 million, while general and administrative expenses rose to $4.3 million from $3.7 million in the prior year period. Net loss was $15.3 million, or $0.31 per share, compared to a net loss of $15.4 million, or $1.14 per share, in Q2 2025. The company continues IND-enabling activities for OKI-345 and OKI-355, with submissions planned for the first half of 2027. OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines targeting PI3Kα-driven diseases.